Read about the new Rx products featured in April.
MARKETED BY: Valeant Pharmaceuticals International
INDICATION: The FDA has approved Siliq (brodalumab) injection for subcutaneous use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond, or have lost response, to other systemic therapies.
DOSAGE FORM: Subcutaneous injection: 210 mg
FOR MORE INFORMATION: valeant.com
SPIRIVA RESPIMAT MARKETED BY: Boehringer Ingelheim
INDICATION: The FDA has expanded the indicated for the approved Spiriva Respimat (tiotropium bromide) for the long-term, once-daily maintenance treatment of asthma in individuals 6 years and older.
DOSAGE FORM: Oral inhalation: 1.25 mcg
FOR MORE INFORMATION: spiriva.com
PARSABIV MARKETED BY: Amgen
INDICATION: The FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on hemodialysis.
DOSAGE FORM: Injection: 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL
FOR MORE INFORMATION: amgen.com
MARKETED BY: Eli Lilly
INDICATION: The FDA approved Eli Lilly’s updated label for its type 2 diabetes drug, Trulicity (dulaglutide), to include use in combination with basal insulin for adults with type 2 diabetes. The FDA included the changes to the approved product labeling to reflect this important information for prescribers.
DOSAGE FORM: Injection: 0.75 and 1.5 mg
FOR MORE INFORMATION: trulicity.com